Navigation Links
Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology
Date:1/28/2008

SOMERSET, N.J., Jan. 28 /PRNewswire/ -- The newest product offered by Terumo is literally expanding the company's interventional device portfolio.

Terumo Interventional Systems announces the launch of the AZUR Peripheral HydroCoil Embolization System for the occlusion of blood vessels, vascular malformations, and aneurysms. AZUR is the only peripheral platinum coil embolization system with a hydrogel coating that expands when introduced into the bloodstream, delivering greater filling and mechanical occlusion - all with fewer coils.

AZUR's hydrogel coating undergoes limited expansion within the first 3 minutes, and fully expands within 20 minutes. The result is greater filling and mechanical stability with fewer coils - nearly 5 times more filling volume for the 0.018" coil and 4 times more filling volume for the 0.035" coil (versus platinum coils of the same size).

In addition to its unique HydroCoil technology, AZUR is the only peripheral embolization system to offer a truly detachable system, giving physicians the ability to detach coils in less than a second and at the push of a button. With the capability to withdraw and reposition the coil until the coil is securely placed, the system minimizes the risk of non-target embolization and coil migration. This offers a whole new level of control, making it ideal for high-flow areas and challenging vascular anatomy.

Dr. Craig Greben, Chief of the Division of Interventional Radiology at the North Shore University Hospital on Long Island in New York, was the first physician to successfully use the AZUR Peripheral HydroCoil Embolization System in his practice. Deploying AZUR in a patient who had 2 large splenic artery aneurysms, Dr. Greben reported that AZUR filled the aneurysm with precision and ease and required fewer coils.

"We believe that AZUR enables interventionalists to approach even the most challenging anatomy with new capability and confidence," says Fernando Yuste, Marketing Manager of Interventional Products for Terumo Interventional Systems. "With the initial feedback that we've received from physicians, we're predicting that AZUR will be the new gold standard for endovascular occlusion of vascular lesions."

For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Customer Care Team at 800-862-4143 or by visiting http://www.terumois.com .

Terumo Interventional Systems

Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists and Vascular Surgeons are among the medical professionals who depend upon TIS products to access and cross difficult-to- reach lesions thereby allowing therapeutic intervention in previously unreachable vascular beds.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $2.3 billion in sales and operations in more than 150 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:JP) and is a component of the Nikkei 225, Japan's leading stock index.


'/>"/>
SOURCE Terumo Interventional Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of ... manage stress and anxiety. , “Buzzies change the way we interact with stress ... Buzzies. , Since its launch date in December 2016, The TouchPoint Solution has sold ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... management and workflow solutions, today named The Resource Group as their 2016 Microsoft ... and partner conference in Newport Beach, CA. The award recognizes The Resource ...
(Date:3/23/2017)... ... 23, 2017 , ... According to the National Sleep Foundation , poor ... the only cause of the sunken-eye look, which can include dark circles or bags ... poor health are likely due to genetics, dehydration, allergies, and losing fat beneath the ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys through ... sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted to ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017   Icertis , the leading ... the cloud, today announced an upgrade to the ... to improve clinical trials contract management. Built on ... the solution speeds up clinical trial contracting while ... (CRO). "The pharmaceutical industry is ...
(Date:3/23/2017)... 23, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: ... integrated commercial company that provides clinically useful molecular ... it has entered into agreements to successfully restructure ... ("RedPath") and concurrently terminate its royalty and milestone ... debt to RedPath amounting to $9.34 million is ...
(Date:3/23/2017)... 2017  Additive Orthopaedics, LLC., an early stage ... kicked off a multi-centered clinical study to measure ... According to Brian McLaughlin , ... structures have already shown tremendous post-operative success and ... wedges from which we have seen evidence of ...
Breaking Medicine Technology: